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Public Health Significance: Pre-Exposure Prophylaxis (PrEP) is a daily antiretroviral medication 
to prevent HIV. 20% of new US HIV diagnoses are among women. Although PrEP has been 
available since 2012, less than 5% of PrEP users are women. Barriers to PrEP use include poor 
risk assessment by women’s health providers, lack of PrEP knowledge among women, and lack 
of PrEP familiarity among women’s health providers. Obstetrician-gynecologists (OB/GYNs) are 
uniquely positioned to assess women’s HIV acquisition risk and increase PrEP utilization. 
Objectives: To describe the development of a clinical protocol and provider education series for 
PrEP delivery in an ambulatory OB/GYN setting. 
Methods: An implementation strategy for PrEP delivery was designed based on an informal 
institutional asset assessment. An evidence-based PrEP protocol was developed with stakeholder 
engagement. Provider knowledge/familiarity with PrEP was identified as a key barrier to PrEP 
access and a multi-modal, interactive lecture series was developed in partnership with local 
community and national HIV/AIDS organizations. 
Results: A clinical protocol was distributed. Women’s health provider education sessions were 
held. Studies monitoring the proportion of PrEP prescriptions filled before and after 
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implementation are ongoing. Demographic data, including reason for initiating and/or 
discontinuing PrEP will be described. 
Discussion: There is little data on implementation of PrEP delivery among OB/GYNs. OB/GYNs 
are uniquely positioned to increase access and utilization of PrEP among women at risk for HIV 
acquisition. This evidence-based implementation strategy may provide a model that can be adapted 
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1.0 Section I: Review of PrEP Among Women 
In the United States, at the end of 2018, there were approximately 1.2 million people living 
with HIV in the US, 20% of which were women. It is estimated that 1 in 9 US women living with 
HIV do not know their HIV status which poses significant treatment and prevention barriers1.  
Among women, HIV disproportionately affects black women. In 2018, 16% of new HIV diagnoses 
occurred in women with 58% of these incident cases (4,097 of 7110) diagnosed among Black 
women, who make up only 13% of the population1. Indeed, the HIV incidence rate among Black 
and Latina women is 15 times and 5 times higher than White women, respectively1. While sexual 
contact is the main HIV transmission category among US women, needle-sharing intravenous drug 
use (nsIVDU) represents a significant means of transmission, particularly among women1.  
The reproductive health of women is also uniquely impacted by HIV infection2. Women 
experience inequity in sequelae of HIV complications of which men do not. These range from 
higher frequency and severity of sexually transmitted diseases (STDs), abnormal cervical 
cytology, menstrual irregularities, and the burden of potential vertical transmission during 
pregnancy2–14. 
In considering gender disparity, HIV risk, and morbidity it is important to acknowledge 
the burden among transgender individuals. Historically, HIV/AIDS surveillance data has focused 
on cisgender women because of challenges in identifying and reporting gender identity in HIV 
surveillance. Transgender-specific data are limited but existing literature reveals that the majority 
of new HIV infections in transgender people occur in transgender women and almost half of those 
are among Black transgender women15. Hindering our understanding of the epidemic in this 
population, nearly two thirds of transgender women and men have never been tested for HIV16.  
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While the authors acknowledge the limitations of gender identity inclusion in the literature, this 
report will use the term ‘woman’ to mean cisgender women. 
1.1 Mode of Viral Transmission 
Empiric data on per contact risk of HIV exposure is limited. Women are at risk for sexual 
acquisition of HIV through both unprotected vaginal and anal intercourse and the percentage of 
diagnoses of HIV infection attributed to heterosexual contact is the most common transmission 
category in the US1. Unprotected receptive anal intercourse (URAI) poses the highest transmission 
risk per sex-act given the significant concentration of immune cells lining the gastrointestinal 
epithelium that are exposed to HIV-infected genital fluid. URAI is not an uncommon practice 
among women but is often underreported. Existing data, albeit limited, has found that over 40% 
of women have engaged in URAI17,18. However, HIV transmission risk per-act of URAI does not 
appear to be different between men and women (approximately one transmission per 72 sex acts) 
17,19. High viral load, the presence of STDs, lack of penile circumcision, as well as other host and 
genetic factors may also influence the efficiency of HIV transmission20. The estimated per-act 
transmission risk for receptive penile-vaginal intercourse is twice as high as that for insertive 
penile-vaginal intercourse (1 per 1250 sex acts vs 1 per 2500 sex acts), thus women are more likely 
to acquire HIV from men than men from women19,20.  
Parenteral transmission through nsIVDU is the second most common transmission 
category for women in the US1. Estimated per-act risk from nsIVDU is approximately 1 in 150 
per-act19. The percentage of new HIV diagnoses attributed to nsIVDU is increasing with the largest 
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percentages among American Indian/Alaska Native (43%) and White women (36%). Diagnoses 
of HIV attributed to perinatal transmission account for 1% of cases among all women.1 
1.2 Review of Biomedical  HIV Prevention Strategies for Women 
There are many current HIV prevention strategies that target different modes of HIV 
transmission. Behavioral interventions targeting individual choices and decision-making have 
been the mainstay of prevention methods for women. These include programs that address barrier 
protection methods, risk perception, comprehensive sex education (such as STD screening and 
types of intercourse), and issues of HIV stigma and discrimination21–23.  
One of the most important advances impacting these types of HIV prevention strategies 
has been the recognition of HIV treatment as HIV prevention. Evidence supporting this concept is 
derived from several large randomized and observational studies among serodiscordant sexual 
partners. These studies demonstrated that the risk of sexual transmission of HIV is negligible when 
a person living with HIV  (PLWH) is virally suppressed for at least six months 24–27. The concept 
of treatment as prevention is also referred to as U=U, or undetectable equals untransmittable, was 
included in the 2019 update of the US official HIV treatment guidelines28. 
 
1.2.1  Oral Pre-Exposure Prophylaxis 
Concomitant STDs, inflammation, tissue concentration of immune cells, genital mucosal 
trauma, and hormonal changes may also mediate infection permissiveness in the cervicovaginal 
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tissue29,30. Female-controlled, discrete, non-coitally dependent interventions are important as they 
enable women to protect themselves when they may not have the position to negotiate other forms 
of safe-sex such as male condom use. Thus, female-controlled methods for preventing HIV are 
critical areas of research and implementation.31  
In 2012, daily oral tenofovir disoproxil fumarate 300mg/emtricitabine 200mg (TDF/3TC), 
in combination with safe sex practices, was approved by the Food and Drug Administration (FDA) 
for use as HIV pre-exposure prophylaxis for all-genders at substantial risk of HIV infection32 This 
2 drug formulation is the only FDA approved oral biomedical PrEP option for women. Oral PrEP 
prevents HIV transmission through sexual activity when these drug concentrations accumulate in 
sufficient levels in mucosal tissue to suppress viral replication30. TDF and 3TC are nucleoside 
reverse transcriptase inhibitors and interfere with HIV viral RNA dependent DNA polymerase 
resulting in inhibition of viral replication.   
While oral TDV/3TC is effective and approved for use as PrEP, there is continued research 
into alternative biomedical interventions. A second formulation of tenofovir, tenofovir 
alafenamide (TAF)  coformulated with 3TC is available as oral PrEP but has not yet been approved 
for those whose primary risk factor for HIV acquisition is receptive vaginal intercourse33. 
1.2.2  Microbiocides 
Microbiocides are products that are designed to prevent the sexual transmission of HIV 
when applied topically to the vagina or rectum. Some of the earliest female-focused microbiocides 
trialed were tenofovir-based gels, foams, and films, and most recently, an anti-retroviral 
impregnated ring29,34. Despite early pharmacokinetic data that demonstrated high levels of 
tenofovir (TDF) concentrations in vaginal mucosa, randomized clinical trials have produced 
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conflicting results regarding the efficacy of topical TDF-based microbiocides in preventing HIV 
infection35. In a trial that assessed efficacy and safety of a TDF 1% vaginal gel, (CAPRISA 004), 
the sexual acquisition of HIV was reduced by 39% overall and by 54% in women with high product 
adherence (adherence >80%) efficacy36–38. Two large clinical trials of a dapivirine (DPV)-
impregnated vaginal ring, the Ring and MTN-020-ASPIRE, demonstrated reductions in HIV 
incidence among women by around 30%. This increased to over 70% in subsequent analyses in 
women who were highly adherent to the product39,4041,42. In July of 2020, the European Medicines 
Agency offered a favorable opinion on the DPV-ring and it is now recommended as a HIV 
prevention choice for women by the WHO43–46. Other promising biomedical interventions, such 
as cabotegravir (CAB) and islatravir, are currently being evaluated in long-acting injectable and 
subcutaneous implant formulations of PrEP. Early phase, gender-inclusive studies are ongoing for 
both antiretrovirals47,48.  
1.3 PrEP Evidence Summary Among Women 
The path to proving HIV prevention efficacy of oral PrEP in women has been challenging. 
Trial results have been conflicting, but the key efficacy study for women has been the Partners 
PrEP trial (Table 1, 2) 49 This was a randomized control trial (RCT) of oral PrEP use among 4758 
heterosexual serodiscordant couples. Sexually active, HIV-1 seronegative women randomized to 
oral TDF/3TC had a 66% reduction in HIV-1 incidence when compared to women assigned to the 
placebo arm. This point estimate was lower than the > 90% reduction reported in previous data 
from studies conducted among men who have sex with men50.  However, in post-hoc analysis, 
when serum levels of were used as a proxy for adherence, a 90% reduction in HIV incidence was 
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observed among women with detectable study drug serum levels. Similar trends have been found 
in other large RCTs. The TDF2 trial, another key trial reporting oral PrEP efficacy in women, 
reported transmission risk was decreased by as much as 71% among women who received oral 
TDF-based PrEP49,51. Conversely, 2 major women-only PrEP trials, VOICE and FEM-PrEP, 
analysis did not demonstrate protective benefit. Post-hoc analysis demonstrated low levels of 
plasma TDF in study participants, consistent with low drug adherence and thus low prevention37,38. 
In an adherence-based meta-analysis of all randomized clinical trials of PrEP efficacy that included 
women, oral PrEP was effective in reducing the sexual transmission of HIV (relative risk 0.39, 















Table 1 Evidence Summary of Randomized Clinical Trials – HIV Incidence Findings 
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Table 2 Measures of Efficacy, by Medication Adherence, Percent Reduction in HIV Incidence in Randomized 
Clinical Trials (95% Confidence Interval) 
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In fact, the majority of trials showed an “intended use” vs ”actual use” phenomenon that 
parallels familiar issues in contraceptive use and efficacy31. Like contraception, PrEP is effective 
if taken as prescribed. The pharmacokinetics of antiretrovirals in genital mucosal tissues are 
governed by a number of complex factors. Indeed, PrEP is less forgiving in terms of missed doses 
when it comes to women29. It takes more doses of oral PrEP to achieve protective levels in the 
vaginal mucosa than the rectal mucosa. Women must ingest a minimum of 6 doses per week to 
benefit from a protective effect29,53. Understanding and identifying barriers to and predictors of 
adherence is critical in maximizing the impact of PrEP for women36,37,54–57.  
Data surrounding efficacy of oral PrEP in preventing HIV transmission from IVDU is 
limited. A randomized, double-blinded, placebo-controlled trial of 2,413 HIV seronegative 
persons with a history of IVDU in the previous year reported a 51.8% (95% CI 15.3-73.7; p=0.01) 
reduction in HIV incidence when comparing TDF-based PrEP with the placebo group in an 
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intention-to-treat analysis. However, in the nested case-control analysis of seronegative 
participants and those with incident HIV infections in the trial, those with detectable TDF plasma 
levels had a 70% (95% CI 2.3-90.6; p=0.04) reduction in HIV incidence58. In this study, all 
participants received one or more comprehensive HIV prevention methods (i.e. risk reduction 
counseling, adherence counseling, condom distribution, and opioid use disorder treatment) and 
thus it is difficult to parse the isolated efficacy of daily oral PrEP among persons who use IV 
drugs59. 
1.4 Pregnancy Considerations for PrEP 
Pregnancy and lactation represent periods of increased HIV acquisition risk60. In a recent 
analysis of women in serodiscordant relationships, risk of HIV acquisition probability per condom-
less sex act steadily increased during each stage of pregnancy and risk was highest in late 
pregnancy and postpartum60. In this study, the risk of HIV acquisition per condom-less sex act was 
3 and 4-fold higher in the pregnant and postpartum periods as compared to the nonpregnant period. 
Some of this risk is thought to be mediated by the hormone related changes in HIV receptor 
expression, vaginal microbiota, and pregnancy related changes in innate immunity. Additionally, 
the frequency of sex acts increases in the postpartum period60.  
These data suggest that biological and behavioral changes during pregnancy and the 
postpartum period increase HIV susceptibility among women. This also carries implications for 
perinatal transmission which is highest in the setting of maternal viremia. TDF/3TC is routinely 
part of anti-retroviral therapy during pregnancy for women living with HIV and the majority of 
safety data come from open-label studies in this population61,62. Unfortunately, pregnant women 
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have been excluded from phase III PrEP clinical trials, but data surrounding peri-conception use 
demonstrated no difference in fertility rates, congenital anomalies or adverse pregnancy outcomes. 
Similar findings are supported by the Antiretroviral Pregnancy Registry, which has followed over 
20,000 pregnancies with ARV exposure61–63. A large meta-analysis and systematic review of data 
from 19 cohorts representing 22,803 total woman years, reviewed all available data on safety of 
TDF in pregnancy and lactating persons and their infants. No statistically significant differences 
were observed in pregnancy incidence, stillbirth/pregnancy loss, preterm delivery less than 37 
weeks, low birth weight <2500/<1500g, small for gestational age, birth defects, or infant (>14 
days) or maternal mortality 64. 
1.5 Breastfeeding Considerations for PrEP 
Data on continuing PrEP while breastfeeding has shown that TDF and 3TC are minimally 
transferred via breastmilk.  Breastfed infants are exposed to only 0.5%-16% of the tenofovir 
dosage that fetuses experienced via placental transfer, and 0.01-0.04% of the recommended 
weight-adjusted therapeutic dose65. In a study of daily oral PrEP in HIV-negative breastfeeding 
women, tenofovir was not detected in 94% of infant plasma samples obtained on day 7 of PrEP 
use when maternal drug concentrations were at steady state. Estimated infant doses of TDF and 
3TC translated into a  <0.01% and 0.5%  relative dose when compared to therapeutic doses of 
these medications for infants66. The WHO recommends continuing PrEP if a woman is at 
continued risk of HIV infection while pregnant and/or breastfeeding67.  In summary, PrEP use in 
pregnancy and breast feeding does not appear to be associated with higher risks of adverse 
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pregnancy and/or infant outcomes. Pregnancy and the postpartum period are periods of heightened 
HIV risk . 
1.6 Unmet PrEP Need Among US Women 
Risk of HIV acquisition varies among US demographic groups because HIV risk reflects 
the likelihood of exposure to HIV.  The likelihood that one is exposed to HIV is a function of  HIV 
prevalence in one’s community and sexual networks. In addition to women’s lack of knowledge 
about PrEP, challenges to identifying women who might from PrEP, and cost concerns, a lack of 
infrastructure to provide PrEP for women in venues where they commonly access healthcare poses 
additional PrEP access barriers. Due to historically gender exclusive marketing of PrEP in the US,  
there is general misconception that PrEP is only for gay men and is accessed through infectious 
disease specialists or clinics that primarily serve gay men or MSM69–81. This has further 
exacerbated the disparity in women’s access to PrEP. 
Unmet PrEP need among women has been defined. Using national HIV surveillance data 
and statistical modeling, the CDC estimated the proportion of adults with indications for PrEP by 
transmission risk factor and race/ethnicity82. Of the 1.1 million adults with indications for PrEP 
use, an estimated 176,670 (15%) were  women yet when this data was cross-referenced with 
national pharmacy data during the same time frame, only 2.1% of PrEP eligible women were 
prescribed PrEP83,84. Inequitable prescription of PrEP may further promote racial and ethnic 
disparities85. For example, among the 1,146 women prescribed PrEP in 2016, 554 (48.3%) were 
white, 297 (25.9%) were black, and 201 (17.5%) were Latina. When compared to the estimated 
1.1 million adults with PrEP indications during that same time, 26.3% were white, 43.7% were 
 12 
black, and 24.7% where Latinx 82,83. These discrepancies can be described quantitatively by an 
indicator called the PrEP-to-Need Ration (PNR). PNR represents the ratio of PrEP users to the 
number of persons newly diagnosed with HIV. It is used to describe whether PrEP use 
appropriately reflects the epidemic need. A lower PNR indicates more unmet need. In the Western 
US, this ratio is 25.9 for women but 7.4 among women in the Southern US, where particularly 
black and women of color are at disproportionate risk of HIV acquisition86–89.  The inequity gap 
between those with PrEP indications and those who are actually prescribed PrEP is significant for 
women and particularly women of color83.  
1.7 PrEP Interest and Utilization Among Women 
Clinics focusing on women’s health are logical places for women to learn about PrEP and 
consider their own risk for HIV. Family planning offices, STD clinics, midwifery practices, and 
OBGYN clinics are all settings with existing structures to support initiation of contraceptive 
medications, which are also sex-dependent medications that require counseling regarding side 
effects and monitoring over time. These structures can be easily adapted to provide PrEP to women 
with risk factors for HIV acquisition. Many studies have sought to assess women’s interest in PrEP 
but few report PrEP utilization in these settings. PrEP interest appears to be as high as 60% among 
women in family planning clinics, and as high as 82% among women in STD clinics90,91. Indeed, 
qualitative focus groups among women sampled from STD clinics show themes that women are 
angry they had not previously known of PrEP and expressed interest in initiation including 
describing PrEP as “life-saving”92. However, one survey among PrEP eligible women within 
Louisiana OBGYN clinics showed that only 54 of 144 (37.5%) women were interested in PrEP. 
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After counseling on PrEP side effects and monitoring requirements, only 4 (2.8%) remained 
interested 93. Notably, of the 54 women who did report interest, 88% felt comfortable discussing 
PrEP with their OBGYN93.   
Of the limited data reporting PrEP utilization in women, one prospective study among 
people presenting for HIV testing at a STD clinic in Texas reported actual PrEP utilization among 
women94. Of 109 women who were eligible for PrEP, 27 were interested and 22 initiated PrEP 
(20%). Comparatively, when PrEP was integrated in a safe syringe program for at-risk women, of 
136 women with IV drug use who were approached, 63 women (46.3%) accepted PrEP 
prescriptions at 1 week. Of these women, 42 (44.2%) reported continuation of PrEP at week 24.  
Thus, while women appear to express interest in preventing HIV acquisition, PrEP 
utilization remains low and may vary by setting95. Qualitative studies have described several 
barriers that impact low PrEP utilization despite high interest among women in options to prevent 
HIV acquisition. These include challenges in understanding personal HIV risk, prior experiences 
with HIV (eg family members dying from HIV-related complications), stigma around HIV 
diagnosis (eg considering it a death sentence), stigma from providers regarding sexual practices, 
and ongoing structural inequities that perpetuate high HIV vulnerability (eg racism, poverty, 
intimate partner violence, etc.) 92,96. The data showing low interest in PrEP among women in 
OBGYN clinics is concerning when compared to other studies assessing women in family planning 
and STD clinic settings. More research is needed to identify the pathway from interest in PrEP to 
actual use of PrEP among women, and to understand what additional barriers there may be within 
OBGYN offices. However, what is clear is that women deserve non-judgmental care and access 
to discussions of HIV risk and PrEP counseling from their women’s health providers. 
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2.0 Section II: Leveraging the Unique Position of Women’s Health Providers to Increase 
Access to PrEP 
Demand for implementation research that promotes the integration of evidence-based 
practices, interventions and policies into routine health care and public health settings is increasing. 
Addressing the intersection of health equity and HIV incidence disparity among women, especially 
women of color, is challenging. International organizations such as the World Health Organization 
(WHO) and the US Agency of International Development’s (USAID’s) Office of HIV/AIDS 
(OHA) have prioritized implementation science that translates HIV prevention research in to 
context-informed health practice97,98. Implementation science, the study of methods to promote the 
adoption and integration of evidence-based practices, interventions and policies into routine health 
care and public health settings, has been central in transitioning health research in to context-
informed health practice97,98. Implementation science related to PreP and women encourages the 
integration of  multi-level, evidence-based strategies for HIV prevention in women. To help 
mitigate disparities in PrEP access and utilization among, women’s health providers are well 
positioned to leverage their proficiency in adapting historically gender-exclusive medical care to 
meet the needs of women, capitalize on their expertise in attention to women’s sexual health 
preferences, and draw from their experience navigating the unique social determinants that mediate 
their HIV risk.99 
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2.1 Determinant Framework to Assess Facilitators & Barriers to PrEP Implementation  
Implementation of PrEP delivery necessitates careful attention to both women’s sexual 
health preferences and the unique social determinants that mediate their HIV risk. The 
consequences of implementation of PrEP delivery strategies without contextual fit can result in 
wasted resources, undue burden on clinic structures, and exacerbation of disparate PrEP 
allocations99. Determinant frameworks identify determinants that contextualize the setting in 
which a strategy or intervention is developed. They do not address how change takes place or 
describe casual mechanisms. Using determinant frameworks imply a systems approach to 
implementation strategies and promote structural thinking from the beginning of strategy 
design100. Thus, frameworks and models, such as the socioecological model, that consider the 
complex relationships between the individual, interpersonal, organizational, community, and 
policy level factors can facilitate exploration of the population-specific factors that influence PrEP 
uptake and identify systemic challenges to PrEP implementation strategies100.  
2.1.1  Contextualizing Through the Socioecological Model 
At this large urban academic women’s hospital, the ambulatory OBGYN clinics were 
identified as a primary point of access for women with vulnerabilities to HIV acquisition. The 
clinic receives Title X Family Planning Program grant funding through the Department of Health 
and Human Services to provide comprehensive family planning and preventative health services 
for low-income or uninsured persons. This population includes low-income women, women of 
color, women with opioid and polysubstance use disorders, women experiencing intimate partner 
violence, unstably housed women, and women with limited English proficiency. To contextualize 
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the powerful individual, social, community, and structural forces that mediate HIV vulnerability 
in this population, the socioecological model was applied and social foundations of structural bias, 
social inequities, and racism were characterized.  
Key end users, community, and project stakeholders were engaged to identify relevant 
factors on each of the levels of the SEM framework. These ranged from patient and provider 
experiences, local community organizations serving cisgender women who would benefit from 
PrEP use, and hospital administrators (Figure 1). 
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Figure 1 The Socioecological Model of the Ambulatory Clinic Setting 
 
Relationships of socio-structural factors unique to the ambulatory care setting were 
characterized through an extensive literature review key stakeholder input, and informal 





Table 3 Social Inequality Factors that Impact HIV Vulnerability in the Ambulatory Clinic Population 
Determinants of HIV Vulnerability  Identified Examples 
Structural Barriers • Provider lack of knowledge & comfort 
prescribing PrEP 
• Intimate Partner Violence 
• Historical trauma & medical mistrust 
• ‘Chief complaint’ disclosure in making clinic 
appointment through central scheduling 
 
-isms • Racism (ie “clinic patient” code) 
• Classism (ie HIV risk implied by class) 
• Linguicism  
• Ageism (ie not screening postmenopausal 
women for HIV) 
 
Social Determinants of Health • Lack of provider diversity  
• Community stigma around condom use, 
seeking HIV testing 
 
Structural Biases • Limited clinic hours/no walk-in clinic 
• Lack of childcare for kids < 2 yo 
Political Determinants of Health • Lack of contact tracing policy in clinic 
Economic Determinants of Health • Hospital parking fees, public transportation 
issues 
• Lab fees outside of clinic fees 
• Co-pays, co-insurance fees 
 
In applying the SEM from the vantage of the OBGYN provider, a key gap in the capacity 
of the ambulatory clinic to integrate PrEP into routine preventative care for cisgender women was 
low provider knowledge and comfort level in prescribing PrEP. Identifying this critical gap in 
PrEP delivery formed the basis of developing an evidence-based implementation strategy for 
integrating PrEP into the ambulatory OBGYN clinic in the form of a targeted provider education 
series and adapted evidence-based PrEP prescribing guidelines 
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2.2 Creating Awareness & Interest: Assessing HIV Risk in Women 
Paramount to optimizing PrEP uptake in US women is performing adequate HIV risk 
assessment and helping women to recognize their risk. Inadequate HIV risk assessment results in 
providers being less likely to classify a woman as “eligible” for PrEP89,99,101. Clinical guidelines 
for implementation of PrEP are published by the US Centers for Disease Control and US Public 
Health Service’s Preexposure Prophylaxis for the Prevention of HIV Infection in the United States-
2017 Update: A Clinical Practice Guideline. The document summarizes PrEP safety and efficacy 
data, provides eligibility criteria for PrEP, outlines parameters for providing and discontinuing 
PrEP, and includes strategies for medication adherence and HIV risk reduction102. 
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Table 4 Comparison of the Two Versions of PrEP Eligibility Criteria Within the US Centers for Disease 








- HIV(+) sexual partner 
- Recent bacterial STD (gonorrhea, 
chlamydia, and/or syphilis)  
- High number of sex partners 
- History of inconsistent/no condom 
use 
- Commercial sex work 
- HIV(+) sexual partner 
- Recent bacterial STI (gonorrhea or 
syphilis) 
- High number of sex partners 
- History of inconsistent/no condom 
use 
- Commercial sex work 
- In high HIV+ prevalence area or 
network  
- HIV(+) injecting partner 




- Adult person 
o without acute or 
o established HIV  
o infection  
- Any sex with opposite partners in 
past 6 months 
- Not in a monogamous partnership 
with a recently tested, HIV(-) 
partner AND 1+ of the following: 
o Any anal sex without condoms 
(receptive or insertive) in past 6 
months 
o A bacterial STD (gonorrhea, 
chlamydia, and/or syphilis) 
diagnosed or reported in past 6 
months 
- Adult person 
o without acute or 
o established HIV 
o infection 
- Any sex with opposite sex partners 
in past 6 months 
- Not in a monogamous partnership 
with a recently tested, HIV(-) 
partner AND 1+ of the following: 
o Is a man who has sex with both 
women and men (behaviorally 
bisexual; see also recommended 
indications for MSM) 
o Infrequently uses condoms during 
sex with 1+ partners of unknown 
HIV status who are known to be 
at substantial risk of HIV 
infection (PWID or bisexual male 
partner) 
o Is in. an ongoing sexual 
relationship with an HIV(+) 
partner 
o Is an ongoing sexual relationship 
with an HIV(+) partner 
o A bacterial STD (gonorrhea, 
syphilis in women or men) 
diagnosed or reported in past 6 
months 
 
- Adult person without acute 
or established HIV infection 
- Any injection of drugs not 
prescribed by a clinician in 
past 6 months AND 1+ of the 
following:  
o Any sharing of injection or 
drug preparation 
equipment in past 6 
months 
o Risk of sexual acquisition 
(see also recommended 
indication for MSM and 
heterosexually active men 
and women) 
 
 The guidelines define PrEP eligibility criteria separately for men who have sex with men, 
heterosexual men and women, and people who inject drugs. These guidelines are presented in 2 
different versions throughout the document - the ‘summary of guidance’ table (p 13) and the 
‘recommended indications for PrEP use’ (p 36-38). In its current form, the 2 versions of the are 
inconsistent in critical ways for women who have risk factors for sexual transmission of HIV.102 
For example, using the summary of a guidance criteria, a woman meets indications for PrEP based 
on her individual risk behavior. Whereas by way of the recommended indications criteria, that 
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same women would be required to also have knowledge of their partner’s HIV risk factors to meet 
criteria for PrEP. Additionally, this latter set of criteria includes stipulations that a woman be able 
to recognize that she has a bacterial STD, despite the fact that these infections can potentially be 
asymptomatic. This is problematic because many providers decide whether to discuss PrEP based 
on these inadequate risk assessments 89,99,101–103.  
The CDC guidelines are the most widely adopted resource for guiding PrEP service 
delivery in the US, with 84% of states and Washington DC having state-level eligibility criteria 
that was adapted from or linked to the CDC guidelines101,103.   However, the guidelines have 
received growing scrutiny regarding their poor sensitivity in being able to consistency identify 
persons who are at risk for HIV acquisition85,104,105. Identified discrepant eligibility criteria that 
disproportionately affect heterosexually active women include: indeterminant categorization of 
individual and structural drivers of HIV risk, vague guidance on PrEP use in the setting of condom 
use and/or viral suppression status of sex partners in serodiscordant couples, and perfunctory 
limitations of sex and gender identity language. These eligibility screening gaps in the guidelines 
risk further deepening disparities in PrEP access for women – particularly those of color85,101,103. 
A recent study examined the ability of the 2 CDC guideline versions to assess PrEP 
eligibility among women who self-disclosed as having existing HIV risk factors and/or endorsed 
motivation to use PrEP. Over 11,000 women receiving care at a Planned Parenthood center were 
surveyed online. The survey assessed PrEP interest, self-perceived HIV risk, and sexual health, 
relationship, and behavioral risk factors for HIV acquisition. HIV-negative women who completed 
all survey items to determine PrEP eligibility were included in the analytic sample (n=679). Of the 
women who reported known HIV risk factors, motivation to take PrEP, or both in the online 
survey, 82.3% of them were eligible for PrEP by summary of guidance criteria compared to 1.5% 
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when recommended indications criteria was applied. These data highlight the inconsistency and 
insensitivity of current guidelines to adequately identify women who could benefit from PrEP101.  
In another study, the CDC eligibility criteria for PrEP were applied to a cohort of women 
without HIV who were enrolled in the Southern US sites of the Women’s Interagency HIV Study 
(a multicenter, observational cohort study of US women living with HIV or are at risk of acquiring 
it)89,106. In this analysis, only 32% of women with pre-defined HIV risk factors met PrEP 
eligibility. When the data was modeled to identify correlates of PrEP eligibility, factors such as 
educational level and history of sexual violence were associated with PrEP eligibility. These 
factors are not currently included in the CDC guidelines89. These data signify the critical need to 
address how women are screened for HIV risk and PrEP eligibility. There is a growing body of 
evidence that acknowledges the shortcomings of how women are currently assessed for HIV risk 
and calls for reform of the guidelines to align the 2 sets of criteria and increase women’s PrEP 
access85,101,107,108. 
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3.0 Section III: Evidence Based Implementation Strategy for Integration of PrEP into 
Routine Reproductive Health Care 
There is limited literature describing the development of evidence-based strategies and 
interventions to integrate oral PrEP into ambulatory reproductive health care for cisgender 
women99,109. Currently, there are no high quality evidence-based or evidence-informed 
interventions or best practices for increasing PrEP initiation and uptake among cisgender 
women110. A strategy to implement an evidence-based intervention, such as oral PrEP, involves 
end user engagement, integrated knowledge translation, and structural thinking in its design. In 
this section, the process of developing an evidence-based implementation strategy for integrating 
PrEP into a large, urban academic ambulatory OBGYN clinic will be described 
3.1 Building Knowledge & Commitment: Addressing Provider Education Gaps in PrEP 
Knowledge 
HIV vulnerability in women is in part mediated by complex psychosocial and structural 
factors and may be amplified by reproductive health providers’ lack of familiarity with  PrEP  and 
comfort with prescribing PrEP111. In a survey administered to US OBGYN providers, 685 of 
providers had heard of PrEP but only 3% had ever prescribed it, even though 78% of providers 
considered their patient population to be at-risk for HIV infection112. Other themes that emerged 
were lack of comfort with current safety and efficacy data of PreP and uncertainty if PrEP could 
be continued in a pregnant patient or not. 71% and 35% of providers reported these concerns112. 
 24 
At a national level, a survey of family planning providers showed less than 50% of providers were 
comfortable with PrEP efficacy data and ordering the correct HIV test after an HIV exposure. 
Targeted curriculum to improve basic PrEP knowledge foundation that is tailored for pregnant, 
breastfeeding, and non-pregnant women are necessary111,112.  
To build provider educational capacity, a targeted educational series was developed to 
address gaps in provider PrEP knowledge and familiarity in prescribing PrEP, identifying women 
who would benefit from PrEP, and improve provider comfort in caring for pregnant, lactating, and 
non-pregnant women who use PrEP.  A multi-modality learning approach was employed through 
the development of a targeted education series for providers in the ambulatory OBGYN clinic. An 
educational lecture series was developed to align with adult learning styles including interactive 
facilitated roleplay, interval “booster” education sessions to promote individual knowledge and 
skill retention, and succinct high-yield content review didactics. The following sections describe 
the three phases of the targeted education series for women’s health providers (Figure 2).   
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3.1.1  Target Audience 
The target audience for the provider education series included all practitioners who 
delivered direct patient care in the ambulatory OBGYN Clinic. This included medical assistants, 
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OBGYN residents, and OBGYN faculty. The core demographic audience consisted primarily of 
physician assistants, OBGYN residents and faculty. Lecture content was made accessible to all 
patient care provider types. 
3.1.2  Curriculum Design & Development 
Lecture format consisted of traditional in-person didactic mode, remote-virtual didactic 
mode, and a recorded structured case presentation with facilitated role-play stratified by learner 
level. In addition to the evidence-based clinical protocol, resources to support PrEP providers 
prescribing and managing PrEP in women were developed in collaboration with the Mid-Atlantic 
AIDS Education Training Center (MAAETC). The MAAETC is one of eight regional Ryan White federally 
funded centers in the US that is administered by the Health Resources and Services Administration under 
the department of Health and Human Services. Among many roles in helping meet the goals of the US 
National HIV/AIDS strategy, the center provides training to health care professionals and organizations on 
the prevention, diagnosis, and treatment of HIV. In this capacity, the MAAETC also provided technical 
and program evaluation support during the interactive role-play session, as well as HIV expert 
clinics to facilitate the role-play session. The following subsections will describe each phase of the 
educational series.   
3.1.2.1 Phase I of Provider Education Series: Foundational Lectures  
Two foundational lectures were delivered to providers in lieu of a regularly scheduled 
weekly educational conference.  Foundational lecture content was developed to address known 
PrEP knowledge gaps among OBGYNs111,112. Content areas included a review of the properties of 
oral PrEP, data regarding PrEP safety and efficacy in women who are non-pregnant, pregnant, 
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and/or lactating, PrEP eligibility criteria for women and important discrepancies in national 
guidelines that pertain to women as discussed above101,103, how to prescribe and monitor PrEP in 
the ambulatory setting, introduction to an evidence-based clinical protocol adapted to the 
ambulatory OBGYN clinic setting (the development of which is discussed in the following 
sections), and introduction to PrEP documentation and prescription in the electronic medical 
record (Appendix 1). 
3.1.2.2 Phase II of Provider Education Series: Focused Lectures 
Given the differentiated range of training-level and experience among the primary target 
residence audience, content lectures were stratified to meet the focused needs of novice learners. 
In this clinical setting, interns (i.e. physicians in their first year of subspecialty training) faced both 
lack of content exposure and lack of logistical experience in the ambulatory clinic.  To address this 
unique intersection of differentiated learner needs, interns identified focused content areas to 
receive additional education in. The clinic administrative chief resident (i.e. senior resident 
physician in final year of subspecialty training) provided additional collateral information 
regarding facilitators and barriers to the operationalization of PrEP delivery in the ambulatory 
OBGYN clinic. These systemic and logistical learning points were incorporated into the focused 
lecture through structured case presentations followed by discussion questions requiring 
hypothetical navigation of clinic infrastructure and electronic medical records. Active learner 
engagement was facilitated through the use of an online, freely available audience response tool. 
This effortful retrieval practice also allowed for real-time identification of knowledge gaps which 
facilitated instruction adaptation to address these areas. Focused content areas included the review 
of PrEP medication properties and side effects, HIV risk assessment in women, patient counseling 
points regarding PrEP use, discontinuation, efficacy, and safety. 
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3.1.2.3 Phase III of Provider Education Series: Skills Application, Facilitated Roleplay, 
Electronic Medical Record Adaptation 
To promote integration and application of PrEP knowledge, an interactive facilitated role-
play training session was developed. A structured case study simulating a telemedicine visit 
between a pregnant patient and her provider was developed and filmed. In this clinical scenario, 
the “patient” discloses behavioral risk factors that increase her risk of STI/HIV acquisition.  
Specific communication skills and learning objectives were developed to help the “provider” and 
“patient” model a conversation on how to navigate HIV risk assessment in women, discussing 
PrEP, reviewing safety and efficacy in pregnancy and lactation, and logistical skills in optimizing 
use of patient encounter notes and PrEP medication order sets in the electronic medical record. 
Payment options were also reviewed. video clips were interjected with narrated slides to highlight 
key learning points and skills that had been demonstrated in the role play, resident, and faculty 
learners were stratified into novice to advanced experience group. Two structured clinical cases 
were developed and specific communication skills and learning objectives were developed for the 
“patient” and “provider” role. These included knowledge application skills in counseling about the 
safety and efficacy of PrEP use in pregnancy and communication skills through the practice of 
helping a patient recognize her personal HIV risk. A complete description of training case 
scenarios, lists of skills, learning goals are detailed in Appendix B. Expert clinicians in HIV 
medicine and patient-centered communication were present to facilitate discussions and provide 
real-time feedback to leaners. 
At the conclusion of the facilitated role-play case scenario, each learner participant was 
guided through navigation of the electronic medical record to complete PrEP related note 
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documentation, medication orders, counseling documentation, and return visits for PrEP 
monitoring. See Appendix C for complete collection of electronic medical record tools. 
A point of care reference for providers was developed and produced by the MAAETC. The 
point of care reference is a succinct review of HIV risk assessment and prevention counseling 
unique to women. Counseling points include messaging specifically for HIV testing during 
specific times in reproductive care (i.e. pregnancy, rapid testing during labor and delivery). See 
Appendix D. 
3.1.2.4 Evaluation of Provider Education Series  
Evaluation of the provider education series was limited to the interactive skills-based 
session. MAAETC evaluation tools were administered via an online, secure digital platform to 
participants. Twenty-nine participants attended the skills-based educational session, 20 of which 
were resident physicians. The post-session survey evaluated multiple domains of provider 
confidence in identifying appropriate candidates for PrEP, prescribing it, and counseling women 
about PrEP use. Additional domains included provider likelihood to use the knowledge/skills 
gained in the learning experience and degree to which the training positively or negatively 
impacted their current clinical practice regarding management of PrEP in women. See Table 5 for 






Table 5 Evaluation Results from MAAETC 
 Extent to which 
residents plan 
to use the 
knowledge/skills 







Extent to which 
residents plan 
to use the 
knowledge/skills 

















Degree to which 
residents agree 







100% (n=5) 80% (n=4/5) 60% (n=3/5) 100% (n= 5/5) 
 
Overall response rate was low (n=5), however, favorable responses were notable in key 
evaluative domains. 100% of residents indicated that they planned to use the knowledge/skills 
gained in the learning experiences in their delivery of HIV prevention and screening services. 60% 
of residents indicated that they intended to seek additional training from HIV experts as a result of 
the learning experience and 100% expressed strongly that they were satisfied with the training 
program as a whole. 
3.1.2.5 PrEP ‘Booster’ Education Sessions 
Short interval, succinct review lectures were designed to facilitate knowledge and skill 
retention among providers. Content topics include foundational knowledge review as well as 
provider generated content topics that are stratified by learner-level. See Appendix A. 
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3.2 Promoting Action & Adoption: Implications for OBGYN Training 
Learning to assess HIV risk in women and being able to provide PrEP is an important 
opportunity for OBGYN’s to improved HIV prevention in women – particularly for those women 
disproportionately affected by the HIV epidemic in the US. Integrating PrEP education into 
OBGYN training is integral to maintaining comprehensive, equitable HIV prevention care 
delivered by physicians that serve as critical access points for women’s healthcare.  As PrEP 
delivery modalities continue to evolve, OBGYN’s are poised to be central in helping to meet the 
diverse needs of women’s unique HIV prevention needs.  
3.3 Pursuing Integration & Sustained Use: Adaptation of Evidence-Based Implementation 
Guidance for PrEP Delivery to Meet Women’s Needs 
To develop a clinical protocol that detailed practice standards of operations and clinical 
guidance for prescribing and monitoring PrEP for women, individuals from key stakeholder groups 
such as pharmacy, social work, clinic administration, and the various levels of providers were 
identified. Hospital leadership was involved early in the protocol development to ensure 
institutional support and oversight. As discussed above, the most widely adopted clinical guidance 
for prescribing PrEP are those published by the  CDC103. With key stakeholder input, an 
institutional protocol to support ambulatory OBGYN providers in prescribing PrEP was adapted 
to meet the needs of the women cared for in this clinic setting.  Existing electronic medical record 
resources for medication order sets, patient counseling, and note templates were adapted from the 
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hospital system electronic repository. The following sections describe the adapted components of 
PrEP delivery guidance for women. 
3.3.1  Laboratory Testing102 
Prior to initiating PrEP, women should be screened for signs and symptoms of acute HIV 
infection in the prior month (i.e. a flu-like illness with fevers, unintentional weight loss, or malaise. 
Based on timing of last high-risk exposure event, HIV testing should be performed to confirm 
seronegativity. Contraindications to oral PrEP containing TDF/3TC include a creatinine clearance 
(CrCl) of less than 60mL/min and a weight above 35 kg. Therefore, baseline serum CrCl must be 
drawn. Hepatitis B status should be assessed and if non-immune, vaccination should be offered. 
TDF has partial-activity against hepatitis B, and thus it is important to determine immunity so as 
to avoid precipitation of the hepatitis B virus (HBV) if PrEP is discontinued. Hepatitis B infection 
is not a contraindication to PrEP use and linkage to an experienced HBV provider is recommended 
for patients found to be HBsAg positive. Women who are non-immune to HBV should be 
vaccinated. Other STD screening, such as gonorrhea, chlamydia, trichomonas, and syphilis should 
be offered for all receptive sexual sites if indicated by sexual practices. 
3.3.2  Providing PrEP102 
Oral PrEP is prescribed as a fixed dose combination of 300mg TDF and 200mg 3TC as a 
single daily dose. A 90-day supply is typically prescribed.  The safety or efficacy in preventing 
HIV acquisition with alternative dosing schedules such as on-demand PrEP (pre/post sex dosing 
only), intermittent, or other episodic schedules have not been studied in women and are not FDA 
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approved for PrEP. PrEP among women should be taken daily, and adherence is critical to effective 
HIV prevention. Side-effects of PrEP are uncommon and usually dissipate within the first month 
of use. Referred to as “start-up syndrome,” short-term initiation side effects include headache, 
nausea, and flatulence. Serious side effects are rare but may include proximal renal tubulopathy 
(Fanconi syndrome), lactic acidosis, elevated liver enzymes 2.5 times the upper limit of normal, 
and decreased bone density. Women should be counseled about signs or symptoms that indicate 
need for urgent medical care such as severe muscle pain and weakness, jaundice, and fragility 
fractures113. Lastly, effective risk-reduction and prevention methods, such as condoms or 
substance abuse treatment referral, should accompany PrEP prescription. 
3.3.3  Insurance Coverage and Financial Support for PrEP  
Financial coverage for PrEP includes both insurance coverage, private, and federal 
subsidies. Many insurance plans will cover the cost of PrEP. However, for uninsured or 
underinsured patients, financial support programs are available such as the Gilead Advancing 
Access and Copay Assistance Programs (available at: https://www.gileadadvancingaccess.com/), 
and “Ready, Set, PrEP” through the Department of Health and Human Services (available at:  
https://www.gileadadvancingaccess.com/copay-coupon-card) 
 
3.3.4  PrEP Monitoring102   
The follow up for PrEP should occur at 3 months intervals for the duration of time that a 
woman is taking PrEP. Three months follow up visits involve re-assessment of HIV risk factors, 
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side effect profile, and patient desire to continue PrEP use. Repeat HIV testing should always occur 
in addition to STD and urine pregnancy testing if applicable. Assessment of creatinine level should 
occur initially at 3 months and then every 6 months thereafter. PrEP should be discontinued in the 
event of a positive HIV test result, or if the CrCl >60ml/kg. If there is a steadily declining CrCl 
despite <60ml/kg, PrEP should still be discontinued. If there is concern for adverse renal effects, 
the patient should be referred to a nephrologist. A summary figure of the adapted CDC guidelines 









HIV risk assessment 
 
Education on PrEP – Basics 
- How it works 
- Adherence 
- Side Effects 
Navigation  
- Insurance coverage 
- Social Support Services 
 
Initial clinic Evaluation 




- Signs/symptoms of acute HIV/STD 
- Kidney disease 
- Medication review 
 
Labs 
- HIV antigen/antibody serum 
test 
- STI, HBV screening 
- Kidney function  
- Pregnancy test 
 
II. PrEP Initiation 
Within 7 days after screening 
Review PrEP Basics Prescribe 90-day supply of PrEP 
 
III. Follow-Up 
Every 3 Months 
- HIV antigen/antibody 
serum test 
- Symptom review 
o Acute HIV infection 
o Side effects 
o STI 




o HIV risk assessment 
o Adherence 
o Pregnancy intent 
 
Every 6 months 
- Labs 
o Kidney function  
o STI if indicate 
 
Adapted from the US Centers for Disease Control and Prevention, Pre-exposure Prophylaxis (PrEP Care System). 




When taken as indicated, PrEP can reduce the risk of acquiring HIV from unprotected sex 
by over 90% and more than 70% from injection drug use106.  Pregnancy and the postpartum period 
are periods of heightened   HIV acquisition. These findings underscore the need for continued 
counseling on the risk of HIV acquisition and options for biomedical HIV prevention in all stages 
of reproductive life. The continuum of HIV prevention for women should also include structural 
interventions that aim to address underlying factors that make women vulnerable to HIV 
acquisition. While these are some of the most difficult interventions to undertake, they may be the 
most cost-effective approaches to mitigate the historical trauma, systemic inequity, and social 
determinants that mediate HIV vulnerability116. Examples of structural interventions 
include programs that promote gender equality, decriminalization of sex work, and programs that 
increase access to school education for young girls116–118. 
PrEP options are changing for women and new delivery systems will provide long-awaited 
choice in HIV prevention options for women. OBGYNs and reproductive health providers are 
uniquely positioned to identify women who would benefit from PrEP and provide it in trusted 
clinical settings. PrEP implementation strategies that consider the complex interplay of 
psychosocial factors that mediate HIV risk for women can help guide translation of innovative 
PrEP research into clinical practice. Targeted curriculum to improve OBGYN competence in 
prescribing PrEP to women has significant potential to increase PrEP access for them. 
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Appendix B Provider Education Series Phase III: Structured Case Scenarios and 
Facilitated Roleplay Guide 
Appendix B.1.1 Structured Case Scenarios 
Breakout Session Format Options: 
• Zoom breakout sessions with expert clinicians as facilitators  
• Option 1: Volunteer provider and patient each read case scenario. List of 
“objectives” reviewed by each participant. Act out scene, facilitator interjects to 
emphasize key points or answer questions 
• Option 2: Volunteer pair picks and objective to role play through. Facilitator 
gives feedback/answers questions, and emphasizes learning points 
• Option 3: Free-style role play. Participants can propose their own case scenarios, 




Patient: You are a 22 yo G2P1 @ 17wga, presenting for routine obstetric care. You disclose 
that you are very stressed out by the FOB. You’ve been in an on and off relationship for several 
years but he is the FOB of your first child. He was recently incarcerated in South Carolina and 
returned to Pittsburgh several months ago and moved in with you because he had nowhere else 
to stay. He is the FOB of this pregnancy but you know he has been unfaithful since he’s been 
back. You received a call from a public health contact tracer last week notifying you that you 
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may have been exposed to syphilis through a sexual contact. You have not had any other sexual 
partners in the last 2 years. Fortunately, all of your testing was negative. Your partner admitted 
to having one other partner but you suspect that he has had multiple since he has been back. 
You do not have any other information on his outside relationships.  
 
Goals for the Patient: 
• Disclose each of the following risk factors through the interview. If the provider does not 
illicit risk factor, creatively bring them up in the conversation  
o Bacterial STDs 
o Unsure of partner’s sexual relationships (number of partners, consistent condom 
use) 
o Partner’s recent incarceration (1 in 5 persons in prison are HIV+. RF include dirty 
injection equipment & IVDU, consensual/non-consensual/coercive/transactional 
sex, dirty/bootleg equipment for tattooing) 
o Inconsistent condom use 
 
Provider: You are an OBGYN in the OPC. Your next patient is a 22 yo pregnant patient who 
is here for routine obstetric care. You do not find anything out of the ordinary on your 
precharting but your MA lets you know that the patient seems upset prior to seeing her.  
   
Goals for the provider/Skills to practice: 
• Identify risk factors for HIV 
• Communicate risk assessment to patient 
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• Ask about PrEP 
• Discuss PrEP benefits/efficacy, risks, alternatives 
• Review pregnancy and breastfeeding safety data 
• Locate and utilize Epic note type, problem-based dot phrase, order set 
• Be aware of patient payment options  
 
Case 2:  
 
Patient: You are a 24yo with two children, who was recently called about a positive gonorrhea 
test. You are coming in for treatment. You have sex with multiple partners, sometimes more 
than one at a time. She sometimes you use condoms and no other forms of birth control. You 
have never heard of PrEP. You feel silly that you have been having sex with so many people, 
but aren’t aware of the risk for STDs or HIV. You are interested in learning about PrEP but 
don’t want to use PrEP yourself.  
 
Goals for the Patient: 
Disclose each of the following risk factors through the interview. If the provider does not illicit 
risk factors, creatively bring them up in the conversation  
• Bacterial STD 
• Multiple sexual partners, Unsure of partner’s sexual relationships (number of partners, 
• consistent condom use 
• Inconsistent condom used 
• Discuss your interest in earning about PrEP 
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• Convey limited understanding of HIV risk factors 
 
Provider: You are an OBGYN in the OPC. Your next patient is coming in for gc+ treatment. 
You do not find anything out of the ordinary on your precharting.  
 
Goals for the provider/Skills to practice: 
• acquire information about her sexual practices 
• support her sexuality while also counseling about PrEP 
Appendix B.1.2 Filmed Sample Case and Facilitate Roleplay Script 
Video Link: https://pitt.app.box.com/s/iym2qr0vyh43n7ik0uj7y2v5kjzp4lv7 
Roleplay Script 
Setting: Recorded Telemedicine Visit - Zoom  
 
Scene 1: MD is in his office chart reviewing his next patient 
Dummy patient in Epic: Zzzpco, Adultfemale - 742174275 
Opens Chart, flashes to still screen with narrated description 
“22 yo G2P1 @ 37wga presents for routine obstetric care.” MA gives you a heads up that 
the patient seems upset but did not disclose anything to her 
 
The objectives of this visit are to: 
• Identify risk factors for HIV 
• Communicate risk assessment to patient 
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• Ask about PrEP 
• Discuss PrEP benefits/efficacy, risks, alternatives 
• Review pregnancy and breastfeeding safety data 
• Locate and utilize Epic note type, problem-based dot phrase, order set 
• Be aware of patient payment options  
 
Scene 2: MD “enters” the virtual patient room, pregnant person as patient 
 
MD: Hi Ms. Williams, how are you feeling today? 
Patient: I’m ok, just stressed.  
MD: Oh yeah? How so? What has been going on? 
Patient: Well, my fiancé has been cheating on me and I’m scared that I’m going to catch 
something from him. I’m scared that it will affect the baby. I got a call from the public 
health department that I might have been exposed to syphilis and I needed to get tested. 
I’ve only been with him but I’ve suspected that he has been with other women since he’s 
been back. I didn’t have any symptoms, but I got tested for everything and all of my 
testing came back negative.  
MD: OMG I’m so sorry to hear this. This sounds so stressful!  
Patient: Thank you, yeah it has been. When I confronted him about the call, he 
eventually came clean about cheating on me last month and getting treated for chlamydia 
and syphilis. He swore it was only one woman but I think it’s been a lot more based on 
some rumors I’ve heard.  
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MD: Thank you for sharing all of this with me, I’m really glad all of your testing has 
come back and I share your concern that his actions could put you and the baby at risk for 
STDs. Are you and your partner still having sex?  
Patient: Not since I got that call. But he’s the father of both of my children and we’re 
working on things. He got out of jail in South Carolina and came straight here because he 
really doesn’t have anywhere else to go.  
 
MD: I hear you, life isn’t always straight forward. But I do want to help you stay 
protected from STDs if you have sex with him again. Do you use condoms when you 
have sex with him? 




Identify risk factors for HIV: 
• Bacterial STDs 
• Unsure of partner’s sexual relationships (number of partners, consistent condom 
use) 
• Partner’s recent incarceration (1 in 5 persons in prison are HIV+. RF include dirty 
injection equipment & IVDU, consensual/non-consensual/coercive/transactional 
sex, dirty/bootleg equipment for tattooing) 
• Inconsistent condom use 
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MD: Ok, that’s not uncommon to hear. Condoms are a good barrier protection from 
STDs but there are other things outside of sex that can increase your risk of contracting 
an STD like HIV too. I know that you have not used drugs before, but do you know if 
your partner has ever used drugs like heroin or meth?  
Patient: He hates needles.  
MD: That’s fair. Has he used these drugs in any other ways? Like taken pills or smoked 
them?  
Patient: Yeah, that’s why he was locked up for 6 months in South Carolina. He was 
smoking heroin and got caught with some old friends that were selling it.  
MD: I see. Do you know much else about his drug use history? Do you know if he’s ever 
traded sex for things like drugs? 
Patient: No. 
 
MD: Ok, and one last question to help me understand some of his risk. Do you know if 
he’s ever had sex with someone who has tested positive for HIV?  
Patient: I have no idea. But who knows? He got syphilis and chlamydia from someone, 
so I doubt he’s asking them about HIV.  
MD: Unfortunately, there aren’t any medications that prevent STDs but there is one that 







Highlight how risk assessment was communicated to patient: 
• Asked her to reflect on a “high risk” sexual behavior of her partner 
• Helped patient recognize risks associated with his lack of monogamy which in 
turn, puts her at risk for STDs/HIV 
• Acknowledged concern about her risk for STD/HIV acquisition 
• Asked about PrEP 
 
Patient: Yeah, but I thought it was only for gay men 
MD: it is actually approved for women too! PrEP reduces the risk of contracting HIV by 
99%.  
Patient: wow! Can I use it while I’m pregnant? 
MD: Yes! The data we have now is limited but has shown that PrEP is safe during 




Discuss PrEP benefits/efficacy 
• Reviewed pregnancy and breastfeeding safety data 
 
Patient: ok, what are the side effects?  
MD: A mild headache and nausea are the most common side effects 
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Patient: Does my insurance cover this medication? 
MD: It depends, but we have many ways of helping people get this medication covered. 
After our visit, social work will come by and help you find coverage.  
Patient: How do I take PrEP? Do I have to have any special tests before starting?  
MD: We’ll need to get a baseline HIV test and some basic labs to check your kidney 
function. In very rare cases, PrEP can affect how your kidneys filter things and may 
cause decreases in bone strength over time.   
Patient: Ok. So how often do I need to take this medication 
MD: PrEP is a daily medication that you take for as long as you need! Especially for 
women, adherence is very important. There isn’t much room for missing doses, women 




Discuss PrEP risks and side effects 
• Be aware of payment options 
• List payment options on screen that are in ambulatory OBGYN clinic  
 
 
Scene 3: Back to MD’s electronic medical record screen.  
 
Show MD opening Pre-exposure prophylaxis Smart set 
Click note type 
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Click Meds, labs, level of service, diagnosis  
RTC in 6 months 
Add patient discharge instructions 
Show MD adding to the problem list: Counseling about HIV 







• Reminder of clinical protocol 
• Use point of care pocket cards/keep on personal cell phone 
• Reproductive Infectious Disease team available for point of care consults 
• Online location of video for reference 
• MAAETEC website and resources 
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Appendix C Electronic Medical Record Adaptations & Documentation 
Appendix C.1 PREP NEW PATIENT NOTE 
PrEP History and Physical 
 




This is a @AGE@ year old {PREP GENDER:31661} here for a new PrEP visit.    
HIV Risk factor is {HIV RISK FACTORS:31662}. 
 
Reason for interest in PrEP: *** 
 
Sex partners are {PREP SEX PARTNERS:31663}.  Has engaged in condomless  
{PREP CONDOMLESS SEX:31664} sex in the past 12 months. 
 
Last condomless penetrative sex (anal/vaginal): *** 
 
Flu like illness in the past 4 weeks {Yes No:31668}. 
 
Date of Last HIV test: *** 
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PAST MEDICAL HISTORY 
@PMH@ 
History of kidney disease {Yes No:31668}. 





SUBSTANCE USE HISTORY 
@SOC@ 
  
Adherence History: Reports {PREP ADHERENCE:31666} missed doses in the past week.   
@LMP@ 
 
REVIEW OF SYSTEMS: 
Fever: {Yes No:31668} 
Lymphadenopathy: {Yes No:31668} 
Diarrhea: {Yes No:31668} 
Nausea: {Yes No:31668} 
Rash: {Yes No:31668} 
Urethral Discharge: {Yes No:31668} 
Rectal Discharge: {Yes No:31668} 
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Vaginal Discharge: {YES NO NA:15678} 
 
PHYSICAL EXAMINATION 
The patient is a {:11314} @SEX@ in {PACT Status:30685}. 
@VS@ 
Affect: {PACT AFFECT:29079} 
Eyes: {PACT EYES:30686} 
ENT: {PACT HEENT:29080} 
Respiratory: {PACT RESPIRATORY:30687} 
Cardiovascular: {HEART ID:11343} 
Gastrointestinal: {GIMA ABDOMEN EXAM:11341} 
Genitourinary: {PACT GENITOURINARY:30688} 
Skin: {IDPE SKIN:60028} 
Lymphatic: {IMMUNE/LYMPHATICS ID:11334} 
 
Most recent HIV result: @LASTLAB(HIV1AB,HIVP24AGSCREEN,HIV2AB)@ 
Most recent Creatinine result: @LASTLAB(SCREAT)@ 
Most recent Syphilis Screen result: @LASTLAB(SYPHILISIGG)@ 
Most recent Gonorrhea result:@LASTLAB(GCAMPLIFIED)@ 
Most recent Chlamydia result:@LASTLAB(CHLAMYDIATRACHOMATISAMPLIFIED)@ 
 





This is a @AGE@ year old {PREP GENDER:31661} here for a new patient visit.    
 
HIV Risk factor is {HIV RISK FACTORS:31662}. 
 
Would like to start use of PrEP.  Discussed the importance of adherence. Other HIV prevention 
modalities such as barrier protection discussed as part of a risk mitigation plan.  Discussed risks 
of PrEP including risk compensation, potential for resistance, and toxicities/side 
effects.  Understands the importance of regular assessments including regular HIV testing and 
creatinine monitor to ensure safety while on PrEP.  Understands the risks and benefits and would 
like to proceed with taking PrEP.  Discussed need to perform STI testing with patient and the 











Appendix C.2 PREP FOLLOW UP NOTE 




• Transgender male  
• Transgender female  




Most recent HIV result: @LASTLAB(HIV1AB,HIVP24AGSCREEN,HIV2AB)@ 
Most recent Creatinine Clearance vs CREATININE W/GFR VS BMP 
Most recent Syphilis Screen result: @LASTLAB(SYPHILISIGG)@ 
Most recent Gonorrhea result:@LASTLAB(GCAMPLIFIED)@ 
Most recent Chlamydia result:@LASTLAB(CHLAMYDIATRACHOMATISAMPLIFIED)@ 
  
Pregnancy/Birth Control Evaluation: 
Current birth control method: {ANNUAL CONTRACEPTION:20532} 
{ANNUAL CONTRACEPTION:20532} 
• None  













• Progestin-only Pill  
• Skyla  





If not on effective birth control, understands the risks/benefits of continuing PrEP in pregnancy 




PrEP Maintenance Questions: 
Have you had any side effects to the PrEP medication? {yes no:26423}, {PrEP Side 
Effects:28887} 




• Abdominal pain  
• Diarrhea  
• other  
Patient counseled on supportive measures (Tylenol, ibuprofen, simethicone, hydration) for side 
effects. {yes no:26423} 
  
Flu like illness in the past 4 weeks {Yes No:31668}. If yes, patient referred to provider. {Yes 
No:31668}. 
In a typical week, how many days do you forget to take your PrEP medication? *** 
If missing any doses, counseled on adherence and risk of HIV. {yes no:26423}   
  
Do you wish to continue PrEP? {yes no:26423} If no, document why patient is discontinuing 
and proceed to discontinuation section. Why discontinuing? *** 
Discussed the importance of adherence. Understands the risks and benefits of continuing 
PrEP.  {YES/NO:63} 
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Discussed need to perform STI testing with patient and the role of condom use given that PrEP 
does not offer protection against STIs. {YES/NO:63} 
  
Every 3 months: 
HIV testing ordered:  {Yes No:31668}. 
Syphilis testing ordered:  {Yes No:31668}. 
GC/CT test sent to lab:  {Yes No:31668}. Sites Sent: Urine, Genital swab, Pharyngeal, Rectal 
Urine pregnancy test result today: {POSITIVE/NEGATIVE:13559::" Negative"}. 
  
Every 6 months: 
Creatinine Clearance ordered:  {Yes No:31668}. 
  
Creatinine Monitoring: 
Creatinine Clearance at initiation of PrEP: *** 
Last Creatinine Clearance level? *** 
If using Truvada, Creatinine Clearance <60ml/kg, patient referred to provider {yes no:26423} 
If using Descovy, Creatinine Clearance <30ml/kg, patient referred to provider {yes no:26423} 
  
If Discontinuing PrEP: 
Reason for discontinuing PrEP? *** 
HepB carrier?  {Yes No:31668}. 
If yes, the patient was counseled on risk of Hepatitis flare and to present for care if experiencing 
yellow-skin, fevers, right upper quadrant pain.  {Yes No:31668}. 
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Patient counseled on risk of HIV transmission after discontinuation of PrEP and ongoing risk 
reduction through condom use and post-exposure prophylaxis.  {Yes No:31668}. 
Patient counseled on need for HIV repeat screening if electing to imitate PrEP again?  {Yes 
No:31668} 
Appendix C.3 Problem List Dot Phrase 
 
Discussed the patient’s eligibility for PrEP, reviewed 99% risk reduction of acquiring HIV when 
PrEP is used daily (in women, need at least 6 doses weekly of Truvada to achieve GU levels that 
are protective, 4 doses per week to achieve levels protective in rectal mucosa). Patient has heard 
of Truvada and is accepting. Discussed that she should have baseline HIV testing prior to starting 
any PrEP method (in addition to baseline Cr testing).  
 
[ ] document neg HIV test 
[ ] assess for any sx of acute HIV infection 
[ ] Serum Cr >60 
[ ] Meet with SW to discuss payment 
[ ] Truvada (TDF/FTC) 90-day supply 
    [ ] Monitoring:  
-Serum cr at 3 mos, then 6 mos thereafter (or however long using PrEP), -STD testing q 3-6 mos 
or as needed.  
-pregnancy test q 3 mos 
57 
*Descovey was approved for PrEP 10/2019, however, is not approved for receptive vaginal sex.
Is approved for receptive anal intercourse. 
Appendix C.4 PrEP Smartest 
Go to “smart sets”-->PrEP smartest → open smart set and navigate through each section. 
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